Nilotinib and a similar drug called dasatinib, marketed as, Sprycel, gained regulatory approval in recent years as backup drugs for imatinib in CML patients who could not tolerate imatinib's side effects or whose cancer had worsened in spite of it. ❋ Unknown (2009)
Small-molecule inhibitors of Lck, such as dasatinib, may function to reverse glucocorticoid resistance in some lymphoid malignancies. glucocorticoids; dexamethasone; calcium; apoptosis; T-cell receptor; Lck ❋ M W Harr (2010)
® and, in some cases, second-line tyrosine kinase inhibitors such as dasatinib and nilotinib. ❋ Unknown (2010)
Some, such as dasatinib, directly inactivate oncogenes. ❋ Siddhartha Mukherjee (2010)
When Sawyers and Talpaz tested dasatinib on Gleevec-resistant patients, the effect was remarkable: the leukemia cells involuted again. ❋ Siddhartha Mukherjee (2010)
In 2009, Mayfield still remains in remission, now on dasatinib. ❋ Siddhartha Mukherjee (2010)
"We understand that trial results are likely to show that dasatinib has comparable-to-better overall tolerability when compared to high-dose Gleevec." ❋ Unknown (2006)
Bristol-Myers Squibb could see heavier trading volume on Friday as an advisory panel to the U.S. Food and Drug Administration will weigh in on the company's cancer treatment, dasatinib, or Sprycel. ❋ Unknown (2006)
In addition, Bristol-Myers plans to launch Orencia for rheumatoid arthritis and dasatinib, a cancer medication, in 2006, said the research analyst. ❋ Unknown (2006)
Both of these older drugs, respectively known generically as dasatinib and nilotinib, are members of a class called tyrosine kinase inhibitors. ❋ Unknown (2011)
In a study in the Journal of the National Cancer Institute, researchers from the Institute of Cancer Research ICR found that Sprycel, known generically as dasatinib and already used in other cancers, reduced bowel cancer cell growth in the lab by blocking the effects of an enzyme called lysyl oxidase, or LOX. ❋ Unknown (2011)
So-called tyrosine kinase inhibitor drugs such as imatinib, marketed by Swiss drugmaker Novartis as Glivec or Gleevec, and dasatinib, sold by Bristol-Myers Squibb as Sprycel, have transformed treatment of CML and are credited with turning it from a fatal cancer into a manageable condition. ❋ Unknown (2011)
Among Thomson Reuters favorites for the Medicine prize are three scientists from the United States -- Brian Druker, Nicholas Lydon and Charles Sawyers -- who discovered and developed ground-breaking new drugs called imatinib and dasatinib for the treatment of chronic myeloid leukemia CML. ❋ Unknown (2011)
"Previous research conducted at MD Anderson found that more patients taking dasatinib were achieving complete responses more quickly than they do on the current standard of care," said ❋ Unknown (2010)
